ArticleCancer immunology research2019
Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 104 citations in OpenAlex.
- Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study.Breast cancer research : BCR · 2025Trial
- Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial.Nature medicine · 2025Trial
- Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer.Nature communications · 2023Trial
- Single-cell RNA sequencing uncovers an immunosuppressive program in PDAC mast cells: tumour-driven activation, proliferation, and association with Treg recruitment.Annals of medicine · 2026Article
- Reprogramming the Immune Landscape of Inflammatory Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The spatial immune landscape predicts outcome and reveals the central role of tumor-associated macrophages in inflammatory breast cancer biology.Breast cancer research : BCR · 2026Article
- Tumor Microenvironment Characterization IdentifiesHuman mutation · 2026Article
- Retinoic Acid Reprograms Mast Cells Toward a Proinflammatory State to Enhance Antitumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Positive and negative roles of myeloid cells in cancer immunotherapy.Journal for immunotherapy of cancer · 2025Review
- Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer.Cell reports. Medicine · 2025Article
- AI-powered prediction model for neoadjuvant chemotherapy efficacy: comprehensive analysis of breast cancer histological images.NPJ precision oncology · 2025Article
- Single-cell transcriptome analysis reveals the malignant characteristics of tumour cells and the immunosuppressive landscape in HER2-positive inflammatory breast cancer.Journal of experimental & clinical cancer research : CR · 2025Article
- Innate Immunity and Platelets: Unveiling Their Role in Chronic Pancreatitis and Pancreatic Cancer.Cancers · 2025Review
- Role of mast cell in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.BMC cancer · 2025Article
- The Cross-talk of Non-coding RNAs and Inflammation in Human Cancer.Current pharmaceutical biotechnology · 2025Review
- Integrative analysis of bulk and single-cell transcriptomics identifies factors related to immunosuppressive microenvironment to predict unfavorable prognosis in inflammatory breast cancer.Frontiers in immunology · 2025Article
- The interplay between the immune response and neoadjuvant therapy in breast cancer.Frontiers in oncology · 2025Review
- Identification of potential diagnostic targets and therapeutic strategies for anoikis-related biomarkers in lung squamous cell carcinoma using machine learning and computational virtual screening.Frontiers in pharmacology · 2025Article
- Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.Cell reports. Medicine · 2024Article
- Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer.NPJ precision oncology · 2024Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 5 institutions in 2 countries.
Sangeetha M ReddyDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Alexandre ReubenDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4510-0382
Souptik BaruaDepartment of Electrical and Computer Engineering, Rice University, Houston, Texas.
Hong JiangDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Shaojun ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Linghua WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Vancheswaran GopalakrishnanDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-8704-035X
Courtney W HudgensDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8312-7485
Michael T TetzlaffDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
James M ReubenDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4510-0382
Takahiro TsujikawaDepartment of Cell, Developmental, and Cancer Biology, Oregon Health and Science University, Portland, Oregon.ORCID 0000-0003-1647-342X
Lisa M CoussensDepartment of Cell, Developmental, and Cancer Biology, Oregon Health and Science University, Portland, Oregon.
Khalida WaniDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yan HeDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lily VillarealMorgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, Texas.
Anita WoodMorgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, Texas.
Arvind RaoDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan.
Wendy A WoodwardMorgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, Texas.
Naoto T Ueno *Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. emittendorf@bwh.harvard.edu jwargo@mdanderson.org skrishna@mdanderson.org nueno@mdanderson.org.ORCID 0000-0002-0166-7275
Savitri Krishnamurthy *Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, Texas. emittendorf@bwh.harvard.edu jwargo@mdanderson.org skrishna@mdanderson.org nueno@mdanderson.org.
Jennifer A Wargo *Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. emittendorf@bwh.harvard.edu jwargo@mdanderson.org skrishna@mdanderson.org nueno@mdanderson.org.
Elizabeth A Mittendorf *Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. emittendorf@bwh.harvard.edu jwargo@mdanderson.org skrishna@mdanderson.org nueno@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USCancer Clinic · USOregon Health & Science University · USUniversity of Michigan · USBrigham and Women's Hospital · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTRAINING FOR ACADEMIC ONCOLOGY/HEMATOLOGYT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, Courtney DiNardo · 1994 to 2026
$9.8MSynthesizing Image-derived Heterogeneity with Genomic measurements for Assessing Disease Aggressiveness in Lower Grade GliomasR37CA214955 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KURTEK, SEBASTIAN, RAO, ARVIND · 2018 to 2024
$3.9MNCI NIH HHS P30 CA016672NCI NIH HHS R37 CA214955NCI NIH HHS T32 CA009666
Abstract
Our understanding is limited concerning the tumor immune microenvironment of inflammatory breast cancer (IBC), an aggressive form of primary cancer with low rates of pathologic complete response to current neoadjuvant chemotherapy (NAC) regimens. We retrospectively identified pretreatment (
Indexed as
Tumor MicroenvironmentAdultAgedChemotherapy, AdjuvantFemaleHistocompatibility Antigens Class IIHumansInflammatory Breast NeoplasmsLymphocytes, Tumor-InfiltratingMacrophagesMast CellsMiddle AgedNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingPrognosisHistocompatibility Antigens Class II
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.